StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
26
Publishing Date
2023 - 10 - 24
1
2023 - 01 - 23
1
2023 - 01 - 09
1
2022 - 12 - 16
1
2022 - 10 - 11
1
2022 - 08 - 25
1
2022 - 04 - 11
2
2022 - 04 - 10
1
2022 - 02 - 15
1
2021 - 11 - 12
1
2021 - 10 - 13
1
2021 - 09 - 28
2
2021 - 09 - 08
1
2021 - 09 - 02
1
2021 - 06 - 29
2
2021 - 06 - 01
2
2021 - 05 - 24
1
2021 - 05 - 04
1
2021 - 04 - 14
1
2021 - 01 - 28
1
2021 - 01 - 07
2
Sector
Health technology
26
Tags
Agreement
25
Alliances
39
Alzheimer's
23
Alzheimer’s
23
Antibody
51
Approval
46
Biomidwest
40
Biopharma
36
Biotech-bay
24
Biotechnology
25
Cancer
139
China
47
Chinese
28
Clinical-trials-phase-iii
32
Collaboration
71
Companies
51
Conference
76
Covid
62
Covid-19
48
Designation
22
Diabetes
57
Disease
89
Drug
105
Earnings
45
Events
32
Expected
24
Fda
71
Financial
65
Financial results
42
Global
149
Growth
108
Health
30
Heart
23
Insulin
37
Iot
23
License
26
Market
305
Meeting
26
Money
34
N/a
1119
Obesity
28
People
70
Pharma
35
Pharmaceutical
24
Phase 1
24
Phase 2
34
Phase 3
47
Positive
30
Report
140
Research
148
Results
203
Risk
24
Study
74
Technology
27
Therapeutics
138
Therapy
88
Tirzepatide
24
Treatment
175
Trial
116
Update
33
Entities
Aclaris therapeutics, inc.
1
Alnylam pharmaceuticals, inc.
2
Biontech se
1
Eli lilly and company
26
Immunogen, inc.
1
Incyte corporation
2
Novo nordisk a/s
2
Precision biosciences, inc.
1
Proqr therapeutics n.v.
1
Takeda pharmaceutical company limited
1
Symbols
ABBV
5
ABEO
7
ADCT
6
ADEA
13
ADXS
6
AGEN
6
ALPMF
17
ALPMY
17
ALVO
8
AQST
5
AZN
16
BGNE
10
BIIB
16
BLIN
5
BMY
12
BNTX
6
CEVA
5
CHRS
6
CPRX
5
CRCW
5
DTIL
5
DYAI
6
EXEL
9
FBIO
9
GILD
13
GMAB
14
GNMSF
11
GSK
10
HALO
6
IDCC
8
IGT
5
IMGN
6
INCY
5
JAGX
6
JAZZ
5
JNJ
45
KMDA
9
LCTX
5
LLY
26
MDT
7
MESO
5
MRK
9
NVO
5
NVS
10
NVSEF
6
OTLK
5
PFE
19
PNT
5
QTRHF
6
SGEN
10
SNY
34
SNYNF
19
SRNE
14
TAK
13
TEVJF
11
TGTX
6
TMDI
6
TNXP
7
VYGR
6
XNCR
6
Exchanges
Nasdaq
9
Nyse
26
Crawled Date
2023 - 10 - 24
1
2023 - 01 - 23
1
2023 - 01 - 09
1
2022 - 12 - 16
1
2022 - 10 - 11
1
2022 - 08 - 25
1
2022 - 04 - 11
3
2022 - 02 - 15
1
2021 - 11 - 12
1
2021 - 10 - 13
1
2021 - 09 - 28
2
2021 - 09 - 08
1
2021 - 09 - 02
1
2021 - 06 - 29
2
2021 - 06 - 01
2
2021 - 05 - 24
1
2021 - 05 - 04
1
2021 - 04 - 14
1
2021 - 01 - 28
1
2021 - 01 - 07
2
Crawled Time
00:00
4
01:00
2
07:00
1
09:00
1
10:00
2
11:00
1
12:00
3
12:03
1
12:07
1
13:00
5
13:20
1
14:00
1
16:00
1
17:00
1
21:00
1
Source
www.biospace.com
16
www.globenewswire.com
2
www.prnewswire.com
8
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
License
symbols :
Lly
save search
Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement
Published:
2023-10-24
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
28.15%
|
O:
-0.84%
H:
0.0%
C:
0.0%
license
research
collaboration
agreement
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
Published:
2023-01-23
(Crawled : 10:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-19.18%
|
O:
-0.25%
H:
0.4%
C:
-0.25%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
116.94%
|
O:
0.16%
H:
0.0%
C:
-1.27%
license
china
TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
Published:
2023-01-09
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
106.86%
|
O:
0.29%
H:
0.27%
C:
-3.89%
collaboration
license
agreement
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
Published:
2022-12-16
(Crawled : 01:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
108.54%
|
O:
-0.58%
H:
0.71%
C:
0.54%
metabolic
collaboration
license
diabetes
agreement
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
Published:
2022-10-11
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
131.8%
|
O:
-1.2%
H:
2.82%
C:
2.38%
research
collaboration
license
therapeutics
agreement
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
Published:
2022-08-25
(Crawled : 12:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
135.45%
|
O:
0.54%
H:
0.86%
C:
0.79%
ACRS
|
$1.23
0.82%
0.81%
560K
|
Health Technology
|
-92.89%
|
O:
1.27%
H:
3.94%
C:
3.94%
patent
license
therapeutics
agreement
Better Together: New Licensing and Collaboration Deals to Watch
Published:
2022-04-11
(Crawled : 16:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
140.87%
|
O:
0.45%
H:
0.21%
C:
-1.32%
BNTX
|
$86.42
0.09%
0.09%
1.2M
|
Health Technology
|
-49.29%
|
O:
-2.44%
H:
3.61%
C:
2.68%
collaboration
license
Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program
Published:
2022-04-11
(Crawled : 13:20)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
140.87%
|
O:
0.45%
H:
0.21%
C:
-1.32%
antibody
program
license
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Published:
2022-04-10
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
140.87%
|
O:
0.45%
H:
0.21%
C:
-1.32%
license
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
Published:
2022-02-15
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
219.9%
|
O:
0.84%
H:
3.44%
C:
3.04%
IMGN
|
$31.23
0.03%
49M
|
Health Technology
|
463.9%
|
O:
2.53%
H:
5.43%
C:
2.11%
license
platform
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Published:
2021-11-12
(Crawled : 14:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
9.62%
|
O:
-0.47%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
185.43%
|
O:
-0.49%
H:
0.0%
C:
0.0%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-16.9%
|
O:
-2.06%
H:
0.0%
C:
0.0%
preclinical
collaboration
research
license
pre-clinical
Hemogenyx Pharmaceuticals Announces CDX Licence Agreement
Published:
2021-10-13
(Crawled : 10:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
222.52%
|
O:
0.55%
H:
1.64%
C:
1.01%
license
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Published:
2021-09-28
(Crawled : 07:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
231.61%
|
O:
-0.0%
H:
0.0%
C:
-2.12%
collaboration
license
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
Published:
2021-09-28
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
231.61%
|
O:
-0.0%
H:
0.0%
C:
-2.12%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-23.88%
|
O:
-0.27%
H:
0.81%
C:
-0.56%
collaboration
license
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
Published:
2021-09-08
(Crawled : 21:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
194.65%
|
O:
-0.08%
H:
0.44%
C:
0.09%
PRQR
|
$1.92
-4.0%
-4.17%
200K
|
Health Technology
|
-72.7%
|
O:
0.0%
H:
0.29%
C:
-2.16%
collaboration
research
license
Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)
Published:
2021-09-02
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
191.67%
|
O:
0.0%
H:
0.9%
C:
0.84%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-31.56%
|
O:
0.23%
H:
0.65%
C:
0.03%
license
Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline
Published:
2021-06-29
(Crawled : 13:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
228.97%
|
O:
0.01%
H:
1.38%
C:
0.49%
license
technology
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal
Published:
2021-06-29
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
228.97%
|
O:
0.01%
H:
1.38%
C:
0.49%
license
technology
AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China
Published:
2021-06-01
(Crawled : 09:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
275.87%
|
O:
0.29%
H:
0.28%
C:
-0.95%
heart
china
license
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China
Published:
2021-06-01
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
275.87%
|
O:
0.29%
H:
0.28%
C:
-0.95%
heart
china
license
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.